Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim ...

Treatment with five-fraction SBRT for prostate cancer may be more convenient than receiving traditional radiation therapy techniques, an expert said. For patients with low- to intermediate-risk ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

Patients with pancreatic cancer who underwent stereotactic body radiation tended to have fewer side effects and treatment sessions compared to those who had intensity-modulated radiation therapy.

The use of magnetic resonance–guided daily adaptive stereotactic body radiotherapy (SBRT) for patients with prostate cancer reduces the risk of acute urinary side effects of grade 2 or higher by 44% ...

International Comparisons of Clinical Demographics and Outcomes in the International Society of Pediatric Oncology Wilms Tumor 2001 Trial and Study We received 395 responses from radiation oncologists ...

An innovative 3D motion management platform for guiding stereotactic body radiation therapy (SBRT) significantly reduced late urinary toxicity in patients treated for prostate cancer compared to a ...

Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...

Stereotactic body radiation therapy, which uses extremely precise, intense doses of radiation, proved to be effective at controlling lung cancer that had spread to a small number of sites. Systemic ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

This prospective study included 135 patients (median age, 67 years; 66 women) who underwent MRI-guided SBRT for liver metastases across seven international centres between April 2019 and April 2023.